IONS Quote, Financials, Valuation and Earnings

Crinetics Pharmaceuticals has a net margin of -111.65% compared to Ionis Pharmaceuticals's net margin of -26807.2%. Ionis Pharmaceuticals's return on equity of -100.15% beat Crinetics Pharmaceuticals's return on equity of -32.07%.

Ionis Pharmaceuticals has a consensus price target of $58.38, signalling upside risk potential of 36.49%. On the other hand Crinetics Pharmaceuticals has an analysts' consensus of $70.38 which suggests that it could grow by 120.61%. Given that Crinetics Pharmaceuticals has higher upside potential than Ionis Pharmaceuticals, analysts believe Crinetics Pharmaceuticals is more attractive than Ionis Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.230, which suggesting that the stock is 77.021% less volatile than S&P 500. In comparison Crinetics Pharmaceuticals has a beta of 0.254, suggesting its less volatile than the S&P 500 by 74.553%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Crinetics Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Crinetics Pharmaceuticals pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $131.6M, which are larger than Crinetics Pharmaceuticals quarterly revenues of $361K. Ionis Pharmaceuticals's net income of -$146.9M is lower than Crinetics Pharmaceuticals's net income of -$96.8M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Crinetics Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 9.11x versus -- for Crinetics Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Esperion Therapeutics has a net margin of -111.65% compared to Ionis Pharmaceuticals's net margin of -62.24%. Ionis Pharmaceuticals's return on equity of -100.15% beat Esperion Therapeutics's return on equity of --.

Ionis Pharmaceuticals has a consensus price target of $58.38, signalling upside risk potential of 36.49%. On the other hand Esperion Therapeutics has an analysts' consensus of $5.79 which suggests that it could grow by 416.58%. Given that Esperion Therapeutics has higher upside potential than Ionis Pharmaceuticals, analysts believe Esperion Therapeutics is more attractive than Ionis Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.230, which suggesting that the stock is 77.021% less volatile than S&P 500. In comparison Esperion Therapeutics has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.654%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Esperion Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Esperion Therapeutics pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $131.6M, which are larger than Esperion Therapeutics quarterly revenues of $65M. Ionis Pharmaceuticals's net income of -$146.9M is lower than Esperion Therapeutics's net income of -$40.5M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Esperion Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 9.11x versus 0.84x for Esperion Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -111.65% compared to Ionis Pharmaceuticals's net margin of -49.65%. Ionis Pharmaceuticals's return on equity of -100.15% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Ionis Pharmaceuticals has a consensus price target of $58.38, signalling upside risk potential of 36.49%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Ionis Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.230, which suggesting that the stock is 77.021% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $131.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ionis Pharmaceuticals's net income of -$146.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 9.11x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -111.65% compared to Ionis Pharmaceuticals's net margin of -1366.49%. Ionis Pharmaceuticals's return on equity of -100.15% beat Recursion Pharmaceuticals's return on equity of -82.61%.

Ionis Pharmaceuticals has a consensus price target of $58.38, signalling upside risk potential of 36.49%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $7.14 which suggests that it could grow by 32.52%. Given that Ionis Pharmaceuticals has higher upside potential than Recursion Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Recursion Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.230, which suggesting that the stock is 77.021% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $131.6M, which are larger than Recursion Pharmaceuticals quarterly revenues of $14.8M. Ionis Pharmaceuticals's net income of -$146.9M is higher than Recursion Pharmaceuticals's net income of -$202.5M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 9.11x versus 28.48x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.